Prescription of antiviral therapy after herpes zoster in general practice: who receives therapy?

Gnann Jr. J.W., Whitley R.J., Clinical practice. Herpes zoster, N Engl J Med, 347, 5, pp. 340-346, (2002)

Thomas S.L., Hall A.J., What does epidemiology tell us about risk factors for herpes zoster?, Lancet Infectious Diseases, 4, 1, pp. 26-33, (2004)

Gauthier A., Breuer J., Carrington D., Et al., Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom, Epidemiol Infect, 137, 1, pp. 38-47, (2009)

Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., Betts R.F., Gershon A.A., Haanpaa M.L., McKendrick M.W., Nurmikko T.J., Oaklander A.L., Oxman M.N., Pavan-Langston D., Petersen K.L., Rowbotham M.C., Schmader K.E., Stacey B.R., Tyring S.K., Van Wijck A.J.M., Wallace M.S., Wassilew S.W., Whitley R.J., Recommendations for the management of herpes zoster, Clinical Infectious Diseases, 44, SUPPL. 1, (2007)

Tyring S., Barbarash R.A., Nahlik J.E., Et al., Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 123, 2, pp. 89-96, (1995)

Wood M.J., Kay R., Dworkin R.H., Soong S.-J., Whitley R.J., Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials, Clinical Infectious Diseases, 22, 2, pp. 341-347, (1996)

Li Q., Chen N., Yang J., Et al., Antiviral treatment for preventing postherpetic neuralgia, Cochrane Database Syst Rev, 2, (2009)

Shingles - Management. When Should I Prescribe An Antiviral Drug?, (2012)

Lewis J.D., Bilker W.B., Weinstein R.B., Strom B.L., The relationship between time since registration and measured incidence rates in the General Practice Research Database, Pharmacoepidemiology and Drug Safety, 14, 7, pp. 443-451, (2005)

Noble M., McLennan D., Wilkinson K., Et al., The English Indices of Deprivation 2007, (2008)

Gnann Jr. J.W., Whitley R.J., Clinical practice. Herpes zoster, N Engl J Med, 347, 5, pp. 340-346, (2002)

Thomas S.L., Hall A.J., What does epidemiology tell us about risk factors for herpes zoster?, Lancet Infectious Diseases, 4, 1, pp. 26-33, (2004)

Gauthier A., Breuer J., Carrington D., Et al., Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom, Epidemiol Infect, 137, 1, pp. 38-47, (2009)

Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., Betts R.F., Gershon A.A., Haanpaa M.L., McKendrick M.W., Nurmikko T.J., Oaklander A.L., Oxman M.N., Pavan-Langston D., Petersen K.L., Rowbotham M.C., Schmader K.E., Stacey B.R., Tyring S.K., Van Wijck A.J.M., Wallace M.S., Wassilew S.W., Whitley R.J., Recommendations for the management of herpes zoster, Clinical Infectious Diseases, 44, SUPPL. 1, (2007)

Tyring S., Barbarash R.A., Nahlik J.E., Et al., Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 123, 2, pp. 89-96, (1995)

Wood M.J., Kay R., Dworkin R.H., Soong S.-J., Whitley R.J., Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials, Clinical Infectious Diseases, 22, 2, pp. 341-347, (1996)

Li Q., Chen N., Yang J., Et al., Antiviral treatment for preventing postherpetic neuralgia, Cochrane Database Syst Rev, 2, (2009)

Shingles - Management. When Should I Prescribe An Antiviral Drug?, (2012)

Lewis J.D., Bilker W.B., Weinstein R.B., Strom B.L., The relationship between time since registration and measured incidence rates in the General Practice Research Database, Pharmacoepidemiology and Drug Safety, 14, 7, pp. 443-451, (2005)

Noble M., McLennan D., Wilkinson K., Et al., The English Indices of Deprivation 2007, (2008)